Literature DB >> 24525081

Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis.

V Terlizzi1, A Tosco1, R Tomaiuolo2, A Sepe1, N Amato1, A Casale1, C Mercogliano1, F De Gregorio1, F Improta1, A Elce2, G Castaldo2, V Raia3.   

Abstract

BACKGROUND: Currently no tools to predict risk of acute (AP) and recurrent pancreatitis (ARP) in children with cystic fibrosis (CF) are available. We assessed the prevalence of AP/ARP and tested the potential role of Pancreatic Insufficiency Prevalence (PIP) score in a cohort of children with CF.
METHODS: We identified two groups of children, on the basis of presence/absence of AP/ARP, who were compared for age at diagnosis, clinical features, genotypes and sweat chloride level. PIP score was calculated for each patient.
RESULTS: 10/167 (5.9%) experienced at least one episode of AP during follow up; 10/10 were pancreatic sufficient (PS). Patients with AP/ARP showed a PIP score ≤0.25 more frequently (6/10) than patients without AP/ARP. The odds ratio (95% CI) of developing pancreatitis was 4.54 (1.22-16.92) for patients with PIP <0.25 when compared with those who have a PIP score >0.25 (p 0.0151). PIP score was correlated with sweat chloride test (p < 0.01).
CONCLUSION: PIP score, PS status and normal/borderline sweat chloride levels could be applied to predict pancreatitis development in children with CF. ARP could lead to pancreatic insufficiency.
Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children; Cystic fibrosis; PIP score; Pancreatitis

Mesh:

Year:  2014        PMID: 24525081     DOI: 10.1016/j.jcf.2014.01.007

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  13 in total

1.  Pancreatic Insufficiency in a Child with p.Gly542* and c.2657+5G>A Heterozygote CFTR: A Case Report.

Authors:  Fernanda Dos Anjos; Jonatha Wruck; Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Débora Tavares de Resende E Silva; Margarete Dulce Bagatini; Sarah Franco Vieira de Oliveira Maciel
Journal:  Clin Med Res       Date:  2022-02-07

Review 2.  Cystic fibrosis from the gastroenterologist's perspective.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01-21       Impact factor: 46.802

Review 3.  Etiology, case fatality, recurrence, and severity in pediatric acute pancreatitis: a meta-analysis of 48 studies.

Authors:  Guo Tian; Lu Zhu; Shuochun Chen; Qiyu Zhao; Tian'an Jiang
Journal:  Pediatr Res       Date:  2021-03-19       Impact factor: 3.756

4.  Association Between Cystic Fibrosis Severity Markers and CFTR Genotypes in Turkish Children.

Authors:  Abdurrahman Erdem Başaran; Ayşen Başaran; Dilara Fatma Kocacik Uygun; Elanur Yılmaz; Asef Moballegh; Latife Öz; Özgül Alper; Ayşen Bingöl
Journal:  Turk Thorac J       Date:  2021-11

5.  S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy.

Authors:  Vito Terlizzi; Antonella Miriam Di Lullo; Marika Comegna; Claudia Centrone; Elisabetta Pelo; Giuseppe Castaldo; Valeria Raia; Cesare Braggion
Journal:  Ital J Pediatr       Date:  2018-01-03       Impact factor: 2.638

6.  CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?

Authors:  Vito Terlizzi; Rita Padoan; Laura Claut; Carla Colombo; Benedetta Fabrizzi; Marco Lucarelli; Sabina Maria Bruno; Alice Castaldo; Paolo Bonomi; Giovanni Taccetti; Antonella Tosco
Journal:  Diagnostics (Basel)       Date:  2020-12-12

7.  Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Krzysztof Dziedzic; Aleksandra Lisowska; Szymon Kurek; Joanna Goździk-Spychalska; Victoria Kononets; Dagmara Woźniak; Edyta Mądry; Jarosław Walkowiak
Journal:  Biomolecules       Date:  2021-02-19

8.  Case Report: White Colored Stool: An Early Sign of Cystic Fibrosis in Infants.

Authors:  Jing Guo; Rong He; Zhi-Qin Mao
Journal:  Front Pediatr       Date:  2021-04-14       Impact factor: 3.418

9.  Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype.

Authors:  Vito Terlizzi; Felice Amato; Chiara Castellani; Beatrice Ferrari; Luis J V Galietta; Giuseppe Castaldo; Giovanni Taccetti
Journal:  Mol Genet Genomic Med       Date:  2021-03-13       Impact factor: 2.183

10.  Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.

Authors:  Annie Dupuis; Katherine Keenan; Chee Y Ooi; Ruslan Dorfman; Marci K Sontag; Lutz Naehrlich; Carlo Castellani; Lisa J Strug; Johanna M Rommens; Tanja Gonska
Journal:  Genet Med       Date:  2015-06-18       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.